Marksans Pharma Share Price Today

Marksans Pharma to join Ashwamedh investor dialogue on September 2

Marksans Pharma to attend Ashwamedh - Elara India Dialogue 2026. Group meet scheduled for September 2, 2026, in Mumbai. Event will be held physically at Hyatt, Santacruz East. No unpublished price sensitive information to be shared.

Marksans Pharma approves ₹0.90 dividend, reappoints directors at AGM

Marksans Pharma shareholders approved a final dividend of ₹0.90 per equity share for FY26. The company’s audited standalone and consolidated financial statements were adopted. Dr. Sunny Sharma was reappointed as director, facing 5.94% opposition from institutional investors. Mrs. Sandra Saldanha was reappointed as Whole-time Director for a three-year term. Promoters participated fully, casting 100% of their eligible votes across all resolutions.

Marksans Pharma Q1 Results: Net profit rises 174% YoY to ₹1,594 crore

Marksans Pharma reported a 174% YoY surge in consolidated net profit to ₹1,594.07 million for Q1FY26, aided by a 36% rise in revenue to ₹8,407.96 million. Key drivers included strong operational growth and a net forex gain of ₹120.01 million. The company also expanded its European footprint by acquiring QliniQ B.V. and ABCnow GmbH.

Marksans Pharma posts record EBITDA of ₹213 cr in Q1FY27

Marksans Pharma delivered record Q1FY27 financials with EBITDA surging 113% YoY to ₹213 crore and PAT rising 174% to ₹159 crore. The UK and Europe region emerged as a key growth engine with record revenue of ₹356 crore. Strong operating leverage improved EBITDA margins by 919 bps to 25.3%, while cash reserves exceeded ₹1,000 crore despite recent acquisitions.

Marksans Pharma publishes notice for 34th annual general meeting

Marksans Pharma Limited announced the publication of its 34th AGM notice in Business Standard and Lakshadeep on August 6, 2026. The filing complies with Regulation 47 of SEBI LODR 2015 and provides shareholders with e-voting and record date details.

Marksans Pharma submits FY26 BRSR with 100% export focus

Marksans Pharma Limited filed its FY26 BRSR report, disclosing a turnover of ₹1,341.47 crores and 100% export contribution. The report highlights governance structures overseen by Chairman Mark Saldanha, environmental initiatives including zero liquid discharge mechanisms, and robust employee welfare policies with no reported grievances on ethical or human rights issues.